BioMerieux SA

BIM: XPAR (FRA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
&!dLOCK|>BgJLOCK|k#rK!BP

BioMerieux's Boost From Currency Changes Offset by Higher Operating Costs; Shares Fairly Valued

BioMerieux’s second-quarter results generally met our expectations, even with higher operating expenses that weighed on margin. We are maintaining our EUR 95 fair value estimate and narrow moat rating.

Sponsor Center